Franklin Resources
KROS icon

Franklin Resources’s Keros Therapeutics KROS Stock Holding History

Franklin Resources’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,756
Closed -$240K – 3280
2026
Q1 		$240K Sell
21,756
-5,826
-21% -$90K ﹤0.01% 2731
2025
Q4 		$562K Sell
27,582
-60,176
-69% -$1.06M ﹤0.01% 2352
2025
Q3 		$1.39M Sell
87,758
-44,543
-34% -$658K ﹤0.01% 1937
2025
Q2 		$1.77M Buy
132,301
+94,006
+245% +$1.27M ﹤0.01% 1755
2025
Q1 		$390K Sell
38,295
-250,133
-87% -$2.9M ﹤0.01% 2369
2024
Q4 		$4.57M Buy
288,428
+194
+0.1% +$10.1K ﹤0.01% 1382
2024
Q3 		$17.4M Sell
288,234
-111,980
-28% -$5.53M ﹤0.01% 934
2024
Q2 		$18.3M Sell
400,214
-231,835
-37% -$12.5M 0.01% 886
2024
Q1 		$41.8M Sell
632,049
-67,376
-10% -$4M 0.01% 635
2023
Q4 		$27.8M Buy
699,425
+226,674
+48% +$7.11M 0.01% 671
2023
Q3 		$15.1M Hold
472,751
– – 0.01% 818
2023
Q2 		$19M Hold
472,751
– – 0.01% 769
2023
Q1 		$20.2M Hold
472,751
– – 0.01% 763
2022
Q4 		$22.7M Sell
472,751
-247
-0.1% -$11.5K 0.01% 740
2022
Q3 		$17.8M Buy
472,998
+118
+0% +$4.09K 0.01% 796
2022
Q2 		$13.1M Buy
472,880
+78,203
+20% +$3.43M 0.01% 889
2022
Q1 		$21.5M Sell
394,677
-11
-0% -$565 0.01% 838
2021
Q4 		$23.1M Buy
394,688
+28
+0% +$1.4K 0.01% 855
2021
Q3 		$15.6M Sell
394,660
-65
-0% -$2.31K 0.01% 952
2021
Q2 		$16.8M Buy
394,725
+134,546
+52% +$7.29M 0.01% 904
2021
Q1 		$16M Buy
260,179
+53
+0% +$3.36K 0.01% 885
2020
Q4 		$18.3M Buy
+260,126
New +$16.4M 0.01% 829

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Franklin Resources's KROS Position: Q2 2026 in Review

Franklin Resources sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 21,756 shares — an estimated $240K sold.

Franklin Resources first reported a position in KROS in Q4 2020 and held it in 22 quarters. The position peaked at $41.8M in Q1 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Franklin Resources reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Franklin Resources sold 21,756 Keros Therapeutics shares in Q2 2026, an estimated $240K.
  • Franklin Resources first reported a position in Keros Therapeutics in Q4 2020 and held it in 22 quarters.
  • Franklin Resources's Keros Therapeutics position peaked at $41.8M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.